Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765212514> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2765212514 endingPage "256" @default.
- W2765212514 startingPage "251" @default.
- W2765212514 abstract "There is no established method for monitoring the anticoagulant effects of apixaban and rivaroxaban. Linear correlation between serum levels and anti-Xa activity has been shown, with r2 ranging from 0.88 to 0.99. However, there are minimal data in patients receiving apixaban 5 mg twice daily or rivaroxaban 20 mg once daily.To evaluate the anti-Xa activity and serum levels at those doses and compare the trough anti-Xa activity.This was a single-center prospective study,approved by the institutional review board. Patients on an inappropriate dose or receiving an interacting drug were excluded. Blood samples were drawn 0.5 to 3 hours before a dose for both agents, 2 to 3 hours after an apixaban dose, and 12 to 16 hours after a rivaroxaban dose. Anti-Xa activity and serum levels were determined, and correlation was done via regression analysis. Trough anti-Xa activity was compared using a t-test.The study enrolled 88 patients receiving each drug. The r2 values were 0.79 and 0.87 for apixaban and rivaroxaban, respectively. The mean trough anti-Xa activity was 1.79 ± 0.96 IU/mL for apixaban and 1.25 ± 0.88 IU for rivaroxaban ( P < 0.01). The trough sample was drawn a mean of 1.3 and 1.8 hours prior to the next dose for apixaban and rivaroxaban, respectively ( P < 0.01).Good correlation was shown between anti-Xa activity and serum levels. The clinical utility of monitoring anti-Xa activity and the significance of the difference in trough anti-Xa activity for these agents remains to be established." @default.
- W2765212514 created "2017-11-10" @default.
- W2765212514 creator A5009741016 @default.
- W2765212514 creator A5024043928 @default.
- W2765212514 creator A5032808914 @default.
- W2765212514 creator A5033147158 @default.
- W2765212514 creator A5079996889 @default.
- W2765212514 creator A5091346353 @default.
- W2765212514 date "2017-10-19" @default.
- W2765212514 modified "2023-10-18" @default.
- W2765212514 title "Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban" @default.
- W2765212514 cites W1547546593 @default.
- W2765212514 cites W1568662837 @default.
- W2765212514 cites W1913131316 @default.
- W2765212514 cites W1963968439 @default.
- W2765212514 cites W2016754244 @default.
- W2765212514 cites W2030594826 @default.
- W2765212514 cites W2040812969 @default.
- W2765212514 cites W2045987573 @default.
- W2765212514 cites W2047003602 @default.
- W2765212514 cites W2073510057 @default.
- W2765212514 cites W2103196751 @default.
- W2765212514 cites W2115787552 @default.
- W2765212514 cites W2126507631 @default.
- W2765212514 cites W2130199362 @default.
- W2765212514 cites W2225937646 @default.
- W2765212514 cites W2277250099 @default.
- W2765212514 cites W2311379003 @default.
- W2765212514 cites W2319663405 @default.
- W2765212514 cites W2520740086 @default.
- W2765212514 cites W2562965755 @default.
- W2765212514 cites W2587483732 @default.
- W2765212514 doi "https://doi.org/10.1177/1060028017738262" @default.
- W2765212514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29047306" @default.
- W2765212514 hasPublicationYear "2017" @default.
- W2765212514 type Work @default.
- W2765212514 sameAs 2765212514 @default.
- W2765212514 citedByCount "13" @default.
- W2765212514 countsByYear W27652125142018 @default.
- W2765212514 countsByYear W27652125142020 @default.
- W2765212514 countsByYear W27652125142021 @default.
- W2765212514 countsByYear W27652125142022 @default.
- W2765212514 countsByYear W27652125142023 @default.
- W2765212514 crossrefType "journal-article" @default.
- W2765212514 hasAuthorship W2765212514A5009741016 @default.
- W2765212514 hasAuthorship W2765212514A5024043928 @default.
- W2765212514 hasAuthorship W2765212514A5032808914 @default.
- W2765212514 hasAuthorship W2765212514A5033147158 @default.
- W2765212514 hasAuthorship W2765212514A5079996889 @default.
- W2765212514 hasAuthorship W2765212514A5091346353 @default.
- W2765212514 hasConcept C126322002 @default.
- W2765212514 hasConcept C2776301958 @default.
- W2765212514 hasConcept C2778205648 @default.
- W2765212514 hasConcept C2778661090 @default.
- W2765212514 hasConcept C2779161974 @default.
- W2765212514 hasConcept C2780638905 @default.
- W2765212514 hasConcept C42219234 @default.
- W2765212514 hasConcept C71924100 @default.
- W2765212514 hasConcept C98274493 @default.
- W2765212514 hasConceptScore W2765212514C126322002 @default.
- W2765212514 hasConceptScore W2765212514C2776301958 @default.
- W2765212514 hasConceptScore W2765212514C2778205648 @default.
- W2765212514 hasConceptScore W2765212514C2778661090 @default.
- W2765212514 hasConceptScore W2765212514C2779161974 @default.
- W2765212514 hasConceptScore W2765212514C2780638905 @default.
- W2765212514 hasConceptScore W2765212514C42219234 @default.
- W2765212514 hasConceptScore W2765212514C71924100 @default.
- W2765212514 hasConceptScore W2765212514C98274493 @default.
- W2765212514 hasIssue "3" @default.
- W2765212514 hasLocation W27652125141 @default.
- W2765212514 hasLocation W27652125142 @default.
- W2765212514 hasOpenAccess W2765212514 @default.
- W2765212514 hasPrimaryLocation W27652125141 @default.
- W2765212514 hasRelatedWork W1997499869 @default.
- W2765212514 hasRelatedWork W2534875391 @default.
- W2765212514 hasRelatedWork W2603244127 @default.
- W2765212514 hasRelatedWork W2738394031 @default.
- W2765212514 hasRelatedWork W2908436399 @default.
- W2765212514 hasRelatedWork W3092155009 @default.
- W2765212514 hasRelatedWork W3173810735 @default.
- W2765212514 hasRelatedWork W3181783855 @default.
- W2765212514 hasRelatedWork W4221134923 @default.
- W2765212514 hasRelatedWork W4245125363 @default.
- W2765212514 hasVolume "52" @default.
- W2765212514 isParatext "false" @default.
- W2765212514 isRetracted "false" @default.
- W2765212514 magId "2765212514" @default.
- W2765212514 workType "article" @default.